Crossmark Global Holdings Inc. bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 21,450 shares of the specialty pharmaceutical company’s stock, valued at approximately $858,000.

Several other hedge funds and other institutional investors have also modified their holdings of SUPN. UBS Asset Management Americas Inc. raised its position in shares of Supernus Pharmaceuticals by 77.4% in the 1st quarter. UBS Asset Management Americas Inc. now owns 17,737 shares of the specialty pharmaceutical company’s stock valued at $555,000 after acquiring an additional 7,737 shares during the period. OppenheimerFunds Inc. acquired a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at approximately $205,000. Teachers Advisors LLC raised its position in shares of Supernus Pharmaceuticals by 1.8% in the 1st quarter. Teachers Advisors LLC now owns 436,121 shares of the specialty pharmaceutical company’s stock valued at $13,651,000 after acquiring an additional 7,861 shares during the period. Vanguard Group Inc. raised its position in shares of Supernus Pharmaceuticals by 6.6% in the 1st quarter. Vanguard Group Inc. now owns 2,516,335 shares of the specialty pharmaceutical company’s stock valued at $78,762,000 after acquiring an additional 156,094 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Supernus Pharmaceuticals by 18.3% in the 1st quarter. Geode Capital Management LLC now owns 447,824 shares of the specialty pharmaceutical company’s stock valued at $14,015,000 after acquiring an additional 69,395 shares during the period. 96.45% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “21,450 Shares in Supernus Pharmaceuticals, Inc. (SUPN) Acquired by Crossmark Global Holdings Inc.” was first published by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/13/21450-shares-in-supernus-pharmaceuticals-inc-supn-acquired-by-crossmark-global-holdings-inc.html.

Shares of Supernus Pharmaceuticals, Inc. (SUPN) opened at $37.25 on Monday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $20.33 and a fifty-two week high of $50.04. The stock has a market cap of $1,909.51, a P/E ratio of 35.14, a PEG ratio of 1.58 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The company had revenue of $80.40 million for the quarter, compared to the consensus estimate of $78.74 million. The firm’s revenue for the quarter was up 41.5% compared to the same quarter last year. equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 1.08 EPS for the current fiscal year.

A number of analysts recently weighed in on the stock. BidaskClub downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. SunTrust Banks, Inc. restated a “buy” rating and set a $61.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, November 3rd. Cowen and Company set a $50.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. Finally, Janney Montgomery Scott restated a “hold” rating and set a $47.00 target price on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Supernus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $49.60.

In other Supernus Pharmaceuticals news, SVP Padmanabh P. Bhatt sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction on Friday, September 8th. The shares were sold at an average price of $49.86, for a total transaction of $249,300.00. Following the completion of the transaction, the senior vice president now directly owns 12,500 shares of the company’s stock, valued at $623,250. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total transaction of $167,758.07. Following the completion of the sale, the vice president now directly owns 17,500 shares of the company’s stock, valued at approximately $791,525. The disclosure for this sale can be found here. Insiders sold 153,709 shares of company stock valued at $7,223,108 over the last three months. 6.70% of the stock is owned by company insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.